1
|
Baghai T, Varallo-Bedarida G, Born C, Haefner S, Schüle C, Eser D, Rupprecht R, Bondy B, von Schacky C. Major depression, cardiovascular risk factors and the Omega-3 index. Eur Psychiatry 2020. [DOI: 10.1016/s0924-9338(11)72310-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
IntroductionCardiovascular disease (CVD) and major depressive disorders (MDD) are frequent diseases worldwide with a high comorbidity rate. Omega-3 fatty acids have been suggested as disease modulators for both CVD and MDD.Objective and aimsTherefore, we studied whether polyunsaturated fatty acids and the Omega-3 Index may represent markers for assessment of the cardiovascular risk in physically healthy patients suffering from MDD.MethodsCase-control study in 166 adults (86 MDD patients without CVD, 80 matched healthy controls). Baseline examinations included depression ratings, conventional cardiovascular risk factors, fatty acid, and interleukin-6 determinations.ResultsSeveral conventional risk factors were more prevalent in MDD patients. The Omega-3 Index and individual omega-3 fatty acids were significantly lower in MDD patients. An Omega-3 Index < 4% was associated with high concentrations of the proinflammatory cytokine IL-6.ConclusionConventional cardiovascular risk factors, the Omega-3 Index and IL-6 indicated an elevated cardiovascular risk profile in MDD patients currently free of CVD. Our results support the employment of strategies to reduce the cardiovascular risk in yet cardiovascularly healthy MDD patients by targeting conventional risk factors and the Omega-3 Index.
Collapse
|
2
|
Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schüle C, Eser D, Zill P, Manook A, Weigl J, Jooyandeh S, Nothdurfter C, von Schacky C, Bondy B, Rupprecht R. Classical Risk Factors and Inflammatory Biomarkers: One of the Missing Biological Links between Cardiovascular Disease and Major Depressive Disorder. Int J Mol Sci 2018; 19:ijms19061740. [PMID: 29895759 PMCID: PMC6032328 DOI: 10.3390/ijms19061740] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Revised: 06/06/2018] [Accepted: 06/08/2018] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Cardiovascular disorders (CVD) and major depressive disorder (MDD) are the most frequent diseases worldwide responsible for premature death and disability. Behavioral and immunological variables influence the pathophysiology of both disorders. We therefore determined frequency and severity of MDD in CVD and studied whether MDD without CVD or other somatic diseases influences classical and inflammatory biomarkers of cardiovascular risk. In addition, we investigated the influence of proinflammatory cytokines on antidepressant treatment outcome. METHODS In a case-control design, 310 adults (MDD patients without CVD, CVD patients, and cardiologically and psychiatrically healthy matched controls) were investigated. MDD patients were recruited after admission in a psychiatric university hospital. Primary outcome criteria were clinical depression ratings (HAM-D scale), vital signs, classical cardiovascular risk factors and inflammatory biomarkers which were compared between MDD patients and healthy controls. RESULTS We detected an enhanced cardiovascular risk in MDD. Untreated prehypertension and signs directing to a metabolic syndrome were detected in MDD. Significantly higher inflammatory biomarkers such as the high sensitivity C-reaktive protein (hsCRP) and proinflammatory acute phase cytokines interleukine-1β (IL-1β) and interleukine-6 (IL-6) underlined the higher cardiovascular risk in physically healthy MDD patients. Surprisingly, high inflammation markers before treatment were associated with better clinical outcome and faster remission. The rate of MDD in CVD patients was high. CONCLUSIONS Patients suffering from MDD are at specific risk for CVD. Precise detection of cardiovascular risks in MDD beyond classical risk factors is warranted to allow effective prophylaxis and treatment of both conditions. Future studies of prophylactic interventions may help to provide a basis for prophylactic treatment of both MDD and CVD. In addition, the high risk for MDD in CVD patients was confirmed and underlines the requirement for clinical attention.
Collapse
Affiliation(s)
- Thomas C Baghai
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstraße 84, D-93053 Regensburg, Germany.
| | - Gabriella Varallo-Bedarida
- Department of Internal Medicine-Preventive Cardiology, Ludwig-Maximilian-University of Munich, Ziemssenstraße 1, D-80336 Munich, Germany.
| | - Christoph Born
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
| | - Sibylle Häfner
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
| | - Cornelius Schüle
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
| | - Daniela Eser
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
| | - Peter Zill
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
| | - André Manook
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstraße 84, D-93053 Regensburg, Germany.
| | - Johannes Weigl
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstraße 84, D-93053 Regensburg, Germany.
| | - Somayeh Jooyandeh
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstraße 84, D-93053 Regensburg, Germany.
| | - Caroline Nothdurfter
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstraße 84, D-93053 Regensburg, Germany.
| | - Clemens von Schacky
- Department of Internal Medicine-Preventive Cardiology, Ludwig-Maximilian-University of Munich, Ziemssenstraße 1, D-80336 Munich, Germany.
| | - Brigitta Bondy
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
| | - Rainer Rupprecht
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Nußbaumstraße 7, D-80336 Munich, Germany.
- Department of Psychiatry and Psychotherapy, University Regensburg, Universitätsstraße 84, D-93053 Regensburg, Germany.
- Max-Planck Fellow at the Max-Planck-Institute for Psychiatry, Kraepelinstraße 2-10, D-80804 Munich, Germany.
| |
Collapse
|
3
|
Spellmann I, Riedel M, Städtler J, Zill P, Obermeier M, Cerovecki A, Dehning S, Schennach R, Epple M, Opgen-Rhein M, Müller N, Bondy B, Möller HJ, Musil R. Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. Cogn Neuropsychiatry 2017; 22:280-297. [PMID: 28470106 DOI: 10.1080/13546805.2017.1322502] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
INTRODUCTION NEUROD2 is a neurospecific helix-loop-helix transcription factor which has an impact on the regulation of glutamatergic and GABAergic genes. We investigated an association of NEUROD2 with neurocognitive dysfunctions in schizophrenia and schizoaffective disorder patients before and during treatment with different second-generation antipsychotics. METHODS Patients were genotyped for four different polymorphisms of the NEUROD2 gene ((rs9889354(A/G), rs1877032(C/T), rs12453682(C/T) and rs11078918(C/G)). Cognitive function was assessed at baseline and week 8. Results of individual neuropsychological tests were assigned to six cognitive domains (reaction time and quality; executive function; working, verbal and visual memory) and a general cognitive index. RESULTS 167 patients were included in the study. The NEUROD2 exonic polymorphism rs11078918 showed significant associations with verbal memory and executive functions, whereas the NEUROD2 polymorphism rs12453682 was significantly associated with working and verbal memory, executive functions and with a cognitive index. Significant associations were found at baseline and after eight weeks. Moreover, significant associations between the change in neuropsychological test results during antipsychotic treatment and the NEUROD2 polymorphisms rs11078918 and rs12453682 were observed. CONCLUSIONS Our findings suggest that the NEUROD2 gene could play a role in the pathophysiology of neurocognitive dysfunctions as well as in the change of cognitive symptoms under antipsychotic treatment in schizophrenia and schizoaffective disorder.
Collapse
Affiliation(s)
- Ilja Spellmann
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Michael Riedel
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Julia Städtler
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Peter Zill
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Michael Obermeier
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Anja Cerovecki
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Sandra Dehning
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Rebecca Schennach
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Maria Epple
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Markus Opgen-Rhein
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Norbert Müller
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Brigitta Bondy
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Hans-Jürgen Möller
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| | - Richard Musil
- a Department of Psychiatry and Psychotherapy , Ludwig-Maximilians-University Munich , Munich , Germany
| |
Collapse
|
4
|
Nothdurfter C, Schmotz C, Sarubin N, Baghai TC, Laenger A, Lieb M, Bondy B, Rupprecht R, Schüle C. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness. J Psychiatr Res 2014; 52:15-20. [PMID: 24513501 DOI: 10.1016/j.jpsychires.2014.01.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2013] [Revised: 01/17/2014] [Accepted: 01/17/2014] [Indexed: 11/16/2022]
Abstract
The hypothalamic-pituitary-adrenocortical (HPA) system is believed to play an important role in the pathophysiology of major depressive disorder. In this context, the atypical antipsychotic quetiapine (QUE) has been shown to inhibit HPA system activity in healthy subjects. In this study we investigated whether the putative inhibitory effects of QUE on HPA system activity may contribute to its antidepressant efficacy. We analyzed the effects of QUE as an augmentation to the selective serotonin reuptake inhibitor (SSRI) escitalopram (ESC) on HPA system activity in comparison to a monotherapy with ESC in relation to the antidepressant effectiveness. HPA axis activity (cortisol and ACTH) was measured by means of the dexamethasone/corticotropin-releasing hormone (DEX/CRH) test which was performed before (week 0) and during (week 1, week 5) antidepressant psychopharmacotherapy. The combination therapy, but not the ESC monotherapy showed significantly inhibiting effects on HPA system activity leading to stepwise down-regulation. ACTH concentrations were reduced in the ESC/QUE group during five weeks of treatment. The inhibitory effect of QUE maybe involved in its antidepressant effects as an augmentation strategy.
Collapse
Affiliation(s)
- Caroline Nothdurfter
- Department of Psychiatry and Psychotherapy, University of Regensburg, Universitätsstrasse 84, 93053 Regensburg, Germany.
| | - Christian Schmotz
- Isar-Amper Klinikum München-Ost, Vockestrasse 72, 85540 Haar, Germany
| | - Nina Sarubin
- Department of Psychiatry and Psychotherapy, University of Regensburg, Universitätsstrasse 84, 93053 Regensburg, Germany; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
| | - Thomas C Baghai
- Department of Psychiatry and Psychotherapy, University of Regensburg, Universitätsstrasse 84, 93053 Regensburg, Germany
| | - Anna Laenger
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
| | - Martin Lieb
- Department of Psychiatry and Psychotherapy, University of Regensburg, Universitätsstrasse 84, 93053 Regensburg, Germany
| | - Brigitta Bondy
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
| | - Rainer Rupprecht
- Department of Psychiatry and Psychotherapy, University of Regensburg, Universitätsstrasse 84, 93053 Regensburg, Germany
| | - Cornelius Schüle
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
| |
Collapse
|
5
|
Daltrozzo T, Albert A, Boldischar A, Holzamer E, Mauer M, Jähnel D, Musil R, Palm U, Mokhtari R, Bauriedl-Schmidt C, Zill P, Renneberg B, Buchheim A, Bondy B, Padberg F, Jobst A. EPA-1574 - Investigating attachment representations of patients with BPD and the regulation of oxytocin in healthy people: adult attachment projective as a challenge paradigm. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78730-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
Preuss UW, Wurst FM, Ridinger M, Rujescu D, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P. Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: results from a large multicenter association study. Drug Alcohol Depend 2013; 133:459-67. [PMID: 23906995 DOI: 10.1016/j.drugalcdep.2013.07.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2012] [Revised: 07/02/2013] [Accepted: 07/02/2013] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Dopamine-beta-hydroxylase (DBH) metabolizes the conversion of dopamine to noradrenaline. DBH, located on chromosome 9q34.2 has variants with potential functional consequences which may be related to alterations of neurotransmitter function and several psychiatric phenotypes, including alcohol dependence (AD), depression (MD) and suicidal behavior (SA). The aim of this association study in a large multicenter sample of alcohol-dependent individuals and controls is to investigate the role of DBH SNPs and haplotypes in AD risk and associated phenotypes (AD with MD or SA). METHOD 1606 inpatient subjects with DSM-IV AD from four addiction treatment centers and 1866 control subjects were included. Characteristics of AD, MD and SA were obtained using standardized structured interviews. After subjects were genotyped for 4 DBH polymorphisms, single SNP case-control and haplotype analyses were conducted. RESULTS rs1611115 (near 5') C-allele and related haplotypes were significantly associated with alcohol dependence in females. This association with female alcohol dependence also accounts for the significant relationship between this variant and comorbid conditions and traits. CONCLUSIONS This study presents evidence for a potentially functional DBH variant influencing the risk for alcohol dependence while other comorbid conditions are not independently influenced by this SNP. However, the study also supports the possible role of the dopamine system in the etiology of female alcohol dependence.
Collapse
Affiliation(s)
- U W Preuss
- Department of Psychiatry, Psychotherapy, Psychosomatics, Martin-Luther-University, Halle-Wittenberg, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur Arch Psychiatry Clin Neurosci 2013; 263:405-12. [PMID: 22965830 DOI: 10.1007/s00406-012-0364-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Accepted: 08/23/2012] [Indexed: 02/03/2023]
Abstract
The role of the brain-derived neurotrophic factor (BDNF) in the pathophysiology of major depressive disorder (MDD) remains to be elucidated. Recent post hoc analyses indicated a potential association of three polymorphisms in the BDNF gene with worse treatment outcome in patients with the subtype of melancholic depression. We aimed at replicating these findings in a German naturalistic multicenter follow-up. Three polymorphisms in the BDNF gene (rs7103411, rs6265 (Val66Met) and rs7124442) were genotyped in 324 patients with MDD and 470 healthy controls. We applied univariate tests and logistic regression models stratifying for depression subtype and gender. The three polymorphisms were not associated with MDD as diagnosis. Further, no associations were found in univariate tests. With logistic regression, we only found a tendency towards an association of the rs6265 (Val66Met) polymorphism with overall response to treatment (response rates: GG (val/val) < GA (val/met) < AA (met/met); p = 0.0129) and some gender differences for the rs6265 (Val66Met) and rs7103411 polymorphisms. Treatment outcome stratified for subtypes of depression did not differ significantly between the investigated polymorphisms or using haplotype analyses. However, results showed a tendency towards significance. At this stage, we cannot support an influence of these three polymorphisms. Further studies in larger patient samples to increase sample sizes of subgroups are warranted.
Collapse
Affiliation(s)
- Richard Musil
- Department of Psychiatry and Psychotherapy, Psychiatric Clinic, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Myint AM, Bondy B, Baghai TC, Eser D, Nothdurfter C, Schüle C, Zill P, Müller N, Rupprecht R, Schwarz MJ. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-γ gene. Brain Behav Immun 2013; 31:128-33. [PMID: 23597432 DOI: 10.1016/j.bbi.2013.04.003] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2012] [Revised: 03/27/2013] [Accepted: 04/07/2013] [Indexed: 12/19/2022] Open
Abstract
The tryptophan metabolism and immune activation play a role in pathophysiology of major depressive disorders. The pro-inflammatory cytokine interferon-γ transcriptionally induces the indoleamine 2,3-dioxygenase enzyme that degrades the tryptophan and thus induces serotonin depletion. The polymorphism of certain cytokine genes was reported to be associated with major depression. We investigated the association between interferon-γ (IFNγ) gene CA repeat polymorphism, the profile of serotonin and tryptophan pathway metabolites and clinical parameters in 125 depressed patients and 93 healthy controls. Compared to controls, serum tryptophan and 5-hydroxyindoleacetic acid (5HIAA) concentrations in the patients were significantly lower and serum kynurenine concentrations were significantly higher at baseline (p<0.0001). The presence of IFNγ CA repeat allele 2 homozygous has significant association with higher kynurenine concentrations in controls (F=4.47, p=0.038) as well as in patients (F=3.79, p=0.045). The existence of interferon-γ CA repeat allele 2 (homo- or heterozygous) showed significant association with increase of tryptophan breakdown over time during the study period (F=6.0, p=0.019). The results indicated the association between IFNγ CA repeat allele 2, tryptophan metabolism and the effect of medication.
Collapse
Affiliation(s)
- Aye Mu Myint
- Department of Psychiatry, Ludwig-Maximilian University Munich, Nussbaumstr. 7, D-80336 Munich, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, Adli M, Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M. Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode. Eur Neuropsychopharmacol 2013; 23:663-74. [PMID: 23063133 DOI: 10.1016/j.euroneuro.2012.08.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2011] [Revised: 08/05/2012] [Accepted: 08/06/2012] [Indexed: 11/26/2022]
Abstract
Factors contributing to treatment-emergent suicidal ideation (TESI) using antidepressants have been in the focus of recent research strategies. We investigated previously established clinical predictors of TESI and combined these with several polymorphisms of candidate genes in patients with major depressive disorder. Common polymorphisms involved in the tryptophan hydroxylase 1 (TPH1) and 2 (TPH2), serotonin transporter, monoamine oxidase A (MAOA) and brain-derived neurotrophic factor (BDNF) were investigated in a naturalistic inpatient study of the German research network on depression. We compared patients showing TESI with non-TESI suicidal patients and with non-suicidal patients using univariate tests to detect relevant factors, which were further tested in logistic regression and CART (Classification and Regression Trees) analyses. Of the 269 patients, TESI occurred in 22 patients (17 female), 117 patients were defined as non-TESI suicidal patients, and 130 patients were classified as non-suicidal. When comparing cases with both control groups we found the TPH2 rs1386494 (C/T) polymorphism to be moderately associated with TESI (Univariate tests: TESI vs. non-suicidality: p=0.005; adjusted: p=0.09; TESI vs. non-TESI suicidal patients: p=0.0024; adjusted: p=0.086). This polymorphism remained the only significant genetic factor in addition to clinical predictors in logistic regression and CART analyses. CART analyses suggested interactions with several clinical predictors. Haplotype analyses further supported a contribution of this polymorphism in TESI. The TPH2 rs1386494 (C/T) polymorphism might contribute to the genetic background of TESI. This polymorphism has been previously associated with committed suicide and major depressive disorder. The small number of cases warrants replication in larger patient samples. Lack of a placebo control group hampers definite conclusions on an association with antidepressive treatment.
Collapse
Affiliation(s)
- Richard Musil
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Carballedo A, Morris D, Zill P, Fahey C, Reinhold E, Meisenzahl E, Bondy B, Gill M, Möller HJ, Frodl T. Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. Am J Med Genet B Neuropsychiatr Genet 2013; 162B:183-90. [PMID: 23341118 DOI: 10.1002/ajmg.b.32130] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Accepted: 12/21/2012] [Indexed: 01/19/2023]
Abstract
The interaction between adverse life events during childhood and genetic factors is associated with a higher risk to develop major depressive disorder (MDD). One of the polymorphisms found to be associated with MDD is the Val66MET polymorphism of brain-derived neurotrophic factor (BDNF). The aim of our two-center study was to determine how the BDNF Val66Met polymorphism and childhood adversity affect the volumetric measures of the hippocampus in healthy individuals and people with MDD. In this two-center study, 62 adult patients with MDD and 71 healthy matched controls underwent high-resolution magnetic resonance imaging. We used manual tracing of the bilateral hippocampal structure with help of the software BRAINS2, assessed childhood adversity using the Childhood Trauma Questionnaire and genotyped Val66Met BDNF SNP (rs6265). MDD patients had smaller hippocampal volumes, both in the left and right hemispheres (F = 5.4, P = 0.022). We also found a significant interaction between BDNF allele and history of childhood adversity (F = 6.1, P = 0.015): Met allele carriers in our samples showed significantly smaller hippocampal volumes when they did have a history of childhood adversity, both in patients and controls. Our results highlight how relevant stress-gene interactions are for hippocampal volume reductions. Subjects exposed to early life adversity developed smaller hippocampal volumes when they carry the Met-allele of the BDNF polymorphism.
Collapse
Affiliation(s)
- Angela Carballedo
- Department of Psychiatry and Institute of Neuroscience, University of Dublin, Trinity College Dublin, Dublin, Ireland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Zill P, Baghai TC, Schüle C, Born C, Früstück C, Büttner A, Eisenmenger W, Varallo-Bedarida G, Rupprecht R, Möller HJ, Bondy B. DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression. PLoS One 2012; 7:e40479. [PMID: 22808171 PMCID: PMC3396656 DOI: 10.1371/journal.pone.0040479] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Accepted: 06/08/2012] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND The angiotensin converting enzyme (ACE) has been repeatedly discussed as susceptibility factor for major depression (MD) and the bi-directional relation between MD and cardiovascular disorders (CVD). In this context, functional polymorphisms of the ACE gene have been linked to depression, to antidepressant treatment response, to ACE serum concentrations, as well as to hypertension, myocardial infarction and CVD risk markers. The mostly investigated ACE Ins/Del polymorphism accounts for ~40%-50% of the ACE serum concentration variance, the remaining half is probably determined by other genetic, environmental or epigenetic factors, but these are poorly understood. MATERIALS AND METHODS The main aim of the present study was the analysis of the DNA methylation pattern in the regulatory region of the ACE gene in peripheral leukocytes of 81 MD patients and 81 healthy controls. RESULTS We detected intensive DNA methylation within a recently described, functional important region of the ACE gene promoter including hypermethylation in depressed patients (p = 0.008) and a significant inverse correlation between the ACE serum concentration and ACE promoter methylation frequency in the total sample (p = 0.02). Furthermore, a significant inverse correlation between the concentrations of the inflammatory CVD risk markers ICAM-1, E-selectin and P-selectin and the degree of ACE promoter methylation in MD patients could be demonstrated (p = 0.01 - 0.04). CONCLUSION The results of the present study suggest that aberrations in ACE promoter DNA methylation may be an underlying cause of MD and probably a common pathogenic factor for the bi-directional relationship between MD and cardiovascular disorders.
Collapse
Affiliation(s)
- Peter Zill
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Schennach R, Zill P, Obermeier M, Hauer D, Dehning S, Cerovecki A, Opgen-Rhein M, Musil R, Spellmann I, Matz J, Krause D, Seemüller F, Müller N, Möller HJ, Bondy B, Riedel M. The CNR1 gene in depression and schizophrenia - is there an association with early improvement and response? Psychiatry Res 2012; 196:160. [PMID: 22370152 DOI: 10.1016/j.psychres.2011.11.021] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Revised: 11/18/2011] [Accepted: 11/23/2011] [Indexed: 11/17/2022]
|
13
|
Koller G, Zill P, Rujescu D, Ridinger M, Pogarell O, Fehr C, Wodarz N, Bondy B, Soyka M, Preuss UW. Possible association between OPRM1 genetic variance at the 118 locus and alcohol dependence in a large treatment sample: relationship to alcohol dependence symptoms. Alcohol Clin Exp Res 2012; 36:1230-6. [PMID: 22309038 DOI: 10.1111/j.1530-0277.2011.01714.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2011] [Accepted: 10/26/2011] [Indexed: 12/13/2022]
Abstract
BACKGROUND Several lines of evidence from previous research indicate that opioid receptors play an important role in ethanol reinforcement and alcohol dependence (AD) risk. Conflicting results were reported on the role of the mu-opioid receptor (OPRM1) polymorphism A118G (Asn40Asp, rs1799971) in the development of alcoholism. METHODS We investigated a total number of 1,845 alcohol-dependent subjects recruited from inpatient facilities in Germany and 1,863 controls for the mu-opioid receptor (OPRM1) polymorphism using chi-square statistics. RESULTS An association between the OPRM variant and AD was detected (p = 0.022), in recessive (AA vs. GA/GG) and co-dominant (AA vs. GA) models of inheritance. An association between the OPRM variant and the DSM-IV criterion "efforts to cut down or could not" (p = 0.047) was found, but this did not remain significant after the correction for multiple testing. CONCLUSIONS The results indicate that this functional OPRM variant is associated with risk of AD and these findings apply to more severe AD, although the association is only nominally significant.
Collapse
Affiliation(s)
- Gabriele Koller
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians University, Munich, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Dreimüller N, Tadić A, Dragicevic A, Boland K, Bondy B, Lieb K, Laux G, Maier W, Müller MJ, Rao ML, Rietschel M, Röschke J, Zill P, Hiemke C. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry 2011; 45:108-13. [PMID: 22086748 DOI: 10.1055/s-0031-1291347] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
INTRODUCTION Both the serotonin transporter promotor polymorphism (5-HTTLPR) and serum concentrations of SSRIs have been shown to affect response to SSRIs. Results, however, are inconsistent. The aim of this study was to investigate whether remission or response to SSRIs is influenced by an interaction of 5-HTTLPR and SSRI serum concentrations. METHODS 49 patients with major depression and SSRI treatment were genotyped for the 5-HTTLPR locus including the rs25531. Drug serum concentrations and depression severity were measured weekly. RESULTS Logistic regression analysis revealed a significant association between 5-HTTLPR, SSRI serum concentrations and response to treatment. A favourable treatment outcome correlated with SSRI serum concentration in 5-HTTLPR-L(A) allele carriers (r² = 34.3 %; p = 0.001), but not in S/L(G)-allele carriers (p = 0.31). DISCUSSION In the group of L(A) allele carriers, those MDD patients with a high antidepressant serum concentrations responded better to treatment than patients with a low serum concentration. We conclude that the 5-HTTLPR might affect reponse to SRRI subject to serum concentrations. If replicated this might be a starting point for prospective clinical trials.
Collapse
Affiliation(s)
- N Dreimüller
- Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Preuss UW, Ridinger M, Rujescu D, Giegling I, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P. Die Zukunft der Suchtmedizin – ... hilft die Genetik weiter? Suchttherapie 2011. [DOI: 10.1055/s-0031-1293181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
16
|
Hutchison K, Claus E, Harlaar N, Bryan A, Grilo CM, Jenkov VP, Toteva S, Jenkov V, Lehert P, VandenBrink W, Preuss UW, Ridinger M, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P, Zimmermann US, Mick I, Lachnit A, Kabus M, Gahr M. FREE ORAL COMMUNICATIONS 7: SUBGROUPS OF ALCOHOL DEPENDENCE AND THEIR SPECIAL TREATMENT * O7.1 * ALCOHOL DEPENDENCE: LINKING GENES WITH INTERMEDIATE NEUROBIOLOGICAL PHENOTYPES. Alcohol Alcohol 2011. [DOI: 10.1093/alcalc/agr123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schüle C, Eser D, Rupprecht R, Bondy B, von Schacky C. Major depressive disorder is associated with cardiovascular risk factors and low Omega-3 Index. J Clin Psychiatry 2011; 72:1242-7. [PMID: 21208589 DOI: 10.4088/jcp.09m05895blu] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2009] [Accepted: 03/15/2010] [Indexed: 10/18/2022]
Abstract
OBJECTIVE Cardiovascular disease (CVD) and major depressive disorder (MDD) are frequent worldwide and have a high comorbidity rate. Omega-3 fatty acids have been suggested as disease modulators for both CVD and MDD. Therefore, we studied whether polyunsaturated fatty acids and the Omega-3 Index may represent markers for assessment of the cardiovascular risk in somatically healthy patients suffering from MDD. METHOD We conducted a case-control study from July 2004 to December 2007 in 166 adults (86 inpatients with MDD but without CVD from the Department of Psychiatry and Psychotherapy and 80 age- and sex-matched healthy controls from an outpatient clinic of the Division of Preventive Cardiology, Ludwig Maximilian University of Munich, Germany). Information gathered at baseline included MDD diagnosis according to DSM-IV criteria, depression ratings, conventional cardiovascular risk factors, and fatty acid and interleukin-6 determinations. Fatty acid composition was analyzed according to the HS-Omega-3 Index methodology. During the study, patients received no supplementation with omega-3 fatty acids. The main inclusion criteria were the diagnosis of MDD according to DSM-IV and a 17-item Hamilton Depression Rating Scale (HDRS-17) score of at least 17. Treatment response and remission were defined using the HDRS-17. RESULTS Several conventional risk factors such as high triglyceride (mean, 152 mg/dL vs 100 mg/dL; P < .001) and fasting glucose (mean, 96 mg/dL vs 87 mg/dL; P = .005) values as well as greater waist circumference (mean, 97 cm vs 87 cm; P = .019) and higher body mass index (calculated as kg/m(2); mean, 26 vs 24; P = .011) were more prevalent in MDD patients in comparison with controls. The Omega-3 Index (mean, 3.9% vs 5.1%; P < .001) and individual omega-3 fatty acids were significantly lower in MDD patients. An Omega-3 Index < 4% was associated with high concentrations of the proinflammatory cytokine interleukin-6 (χ(2) = 7.8, P = .02). CONCLUSIONS Conventional cardiovascular risk factors, the Omega-3 Index, and interleukin-6 levels indicated an elevated cardiovascular risk profile in MDD patients currently free of CVD. Our results support the employment of strategies to reduce the cardiovascular risk in still cardiovascularly healthy MDD patients by targeting conventional risk factors and the Omega-3 Index.
Collapse
Affiliation(s)
- Thomas C Baghai
- Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Nussbaumstrasse 7, D-80336 Munich, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Samochowiec J, Grzywacz A, Jablonski M, Jasiewicz A, Bienkowski P, Preuss U, Ridinger M, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P, Wojnar M, Jakubczyk A, Matsumoto H, Habrat B, Heinz A, Muller CA, Beck A, Charlet C. S23 * NEUROBIOLOGICAL ENDOPHENOTYPES IN ALCOHOL DEPENDENCE * S23.1 * GENETIC DETERMINANTS OF ALCOHOL ADDICTION: SEARCHING FOR AN ENDOPHENOTYPE ASSOCIATED WITH SWEET LIKING IN POPULATION OF FAMILIES WITH HISTORY OF ALCOHOL ADDICTION. Alcohol Alcohol 2011. [DOI: 10.1093/alcalc/agr113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Zill P, Preuss UW, Koller G, Bondy B, Soyka M. Lack of association between SNPs in the NEUROD2 gene and alcohol dependence in a German patient sample. Psychiatry Res 2011; 187:220-3. [PMID: 20880594 DOI: 10.1016/j.psychres.2010.08.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2010] [Revised: 08/20/2010] [Accepted: 08/29/2010] [Indexed: 10/19/2022]
Abstract
Results of a human post mortem study performed by our own group have suggested that the transcription factor NEUROD2, which plays a role in neuronal development, as well as in the development of anxiety and risk behavior in mice, might be a susceptibility factor for addictive disorders. Therefore the aim of the present study was to analyze a possible relation between genetic variants in the NEUROD2 gene and alcohol dependence in a sample of the Munich Gene Bank of Alcoholism (MGBA). We performed single SNP (single nucleotide polymorphism) and haplotype studies in 430 alcohol-dependent patients and 365 healthy controls with four SNPs covering the gene region of NEUROD2. Neither single SNP nor haplotype analysis could detect significant associations with alcohol dependence. Additionally we could not detect any relation of the analyzed genetic variants to Cloninger's Type 1/2 or Babor's Type A/B classification, to the age of onset or to the amount of alcohol intake. Our results do not provide evidence for an involvement of NEUROD2 polymorphisms in the pathophysiology of alcohol dependence. Further association studies are needed to confirm our findings.
Collapse
Affiliation(s)
- Peter Zill
- Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
| | | | | | | | | |
Collapse
|
20
|
Preuss UW, Ridinger M, Rujescu D, Samochowiec J, Fehr C, Wurst FM, Koller G, Bondy B, Wodarz N, Debniak T, Grzywacz A, Soyka M, Zill P. Association of ADH4 genetic variants with alcohol dependence risk and related phenotypes: results from a larger multicenter association study. Addict Biol 2011; 16:323-33. [PMID: 20626721 DOI: 10.1111/j.1369-1600.2010.00236.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Genetic variants of the alcohol-metabolizing enzyme ADH4, located on chromosome 4q22-4q23, have been related to alcohol dependence (AD) risk in previous research. The aim of this association study in a large multicenter sample of alcohol-dependent individuals and controls is to confirm ADH4 single nucleotide polymorphism (SNP) and haplotype association with AD and relevant related phenotypes. One thousand, six hundred and twenty-two (1622) inpatient subjects and 1469 control subjects with DSM-IV. AD from four addiction treatment centres were included. Characteristics of AD and related phenotypes including alcohol withdrawal, Cloninger's type I and II and first ages of drinking, regular drinking and AD onset were obtained using standardized structured interviews. After subjects were genotyped for 2 ADH4 polymorphisms, single SNP case-control and haplotype analyses were conducted. Both variants--rs1800759 and rs1042364--and the A-A and C-G haplotypes were significantly related to AD across samples. Furthermore, associations with AD-related phenotypes and subtypes revealed a potential protective influence of this haplotype. This study confirms the significant relationship of ADH4 variants with AD and related phenotypes. While the rs1800759 and rs1042364 A-A haplotype had a potential protective influence on the risk for several AD-related phenotypes, this effect is rather small compared to functional variants of other alcohol or acetaldehyde-metabolizing enzymes like ALDH2*2 or ADH1B*2.
Collapse
Affiliation(s)
- Ulrich W Preuss
- Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University, Halle-Wittenberg, Julius-Kühn-Str. 7, D–06112 Halle, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Zill P, Vielsmeier V, Büttner A, Eisenmenger W, Siedler F, Scheffer B, Möller HJ, Bondy B. Postmortem proteomic analysis in human amygdala of drug addicts: possible impact of tubulin on drug-abusing behavior. Eur Arch Psychiatry Clin Neurosci 2011; 261:121-31. [PMID: 20686780 DOI: 10.1007/s00406-010-0129-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2009] [Accepted: 07/23/2010] [Indexed: 10/19/2022]
Abstract
Besides the ventral tegmental area and the nucleus accumbens as the most investigated brain reward structures, several reports about the relation between volume and activity of the amygdala and drug-seeking behavior have emphasized the central role of the amygdala in the etiology of addiction. Considering its proposed important role and the limited number of human protein expression studies with amygdala in drug addiction, we performed a human postmortem proteomic analysis of amygdala tissue obtained from 8 opiate addicts and 7 control individuals. Results were validated by Western blot in an independent postmortem replication sample from 12 opiate addicts compared to 12 controls and 12 suicide victims, as a second "control sample". Applying 2D-electrophoresis and MALDI-TOF-MS analysis, we detected alterations of beta-tubulin expression and decreased levels of the heat-shock protein HSP60 in drug addicts. Western blot analysis in the additional sample demonstrated significantly increased alpha- and beta-tubulin concentrations in the amygdala of drug abusers versus controls (P = 0.021, 0.029) and to suicide victims (P = 0.006, 0.002). Our results suggest that cytoskeletal alterations in the amygdala determined by tubulin seem to be involved in the pathophysiology of drug addiction, probably via a relation to neurotransmission and cellular signaling. Moreover, the loss of neuroprotection against stressors by chaperons as HSP60 might also contribute to structural alteration in the brain of drug addicts. Although further studies have to confirm our results, this might be a possible pathway that may increase our understanding of drug addiction.
Collapse
Affiliation(s)
- P Zill
- Department of Psychiatry, Division of Psychiatric Genetics and Neurochemistry, Ludwig-Maximilians-University Munich, Nussbaumstrasse 7, 80336 Munich, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
OBJECTIVES Psychiatric disorders are among the most heritable common disorders, and for more than 20 years researchers have tried to unravel genetic susceptibility genes. This review briefly outlines the pros and cons of genetic approaches, important advances and possible future directions for readers not familiar with genetic studies. METHODS In this article the results of 20 years molecular genetics in psychiatry are shortly and critically summarized on the basis of important reviews and meta-analyses of the last decade, without describing and enumerating the different findings (see special reviews). RESULTS Conventional linkage and candidate association studies revealed numerous, but also inconsistent and sometimes contradictory results. The reasons are assumed to include the complexity of the disorder with interaction of several genes of small effects, lack of a valid phenotype, and invalid statistical and methodological issues. Recent systematic genome-wide association studies (GWAS) have reported association of some common variants for schizophrenia and bipolar disorder. However, the risk conferred by these variants is small and genome-wide significance is rare. Also structural variations might be important, and interesting data are arising from copy-number-variations (CNVs). CONCLUSIONS Although the new data from GWAS are promising, they still do not meet our initial expectations, identifying a "susceptibility gene". However, they opened new aspects concerning aetiology of psychoses, and the incorporation of new approaches, as epigenetics, or gene-environment interaction, is needed in future study designs.
Collapse
Affiliation(s)
- Brigitta Bondy
- Psychiatric Clinic of University Munich, Section Psychiatric Genetics and Neurochemistry, Munich, Germany.
| |
Collapse
|
23
|
Muhtz C, Zyriax BC, Bondy B, Windler E, Otte C. Association of a common mineralocorticoid receptor gene polymorphism with salivary cortisol in healthy adults. Psychoneuroendocrinology 2011; 36:298-301. [PMID: 20832946 DOI: 10.1016/j.psyneuen.2010.08.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2010] [Revised: 07/16/2010] [Accepted: 08/05/2010] [Indexed: 10/19/2022]
Abstract
A common polymorphism of the mineralocorticoid receptors (MR) gene has been associated with cortisol levels after dexamethasone. However, if and how this MR gene variant affects basal cortisol secretion throughout the day is unknown. The aim of our study was to examine the association between the MR gene polymorphism -2G/C (rs2070951) and salivary cortisol measured at four time points during the day in the Stress, Atherosclerosis, and ECG Study (STRATEGY). We recruited healthy adults from the general population (n=133, distributed equally across four age groups, 30-70 years). Salivary cortisol was assessed at 0800, 1200, 1600 and 2200 h. We found a significant effect of genotype indicating that homozygous G allele carriers had higher overall salivary cortisol levels (F=4.5, p=0.01). Furthermore, we found a significant time × group interaction indicating that the group effect was predominantly driven by higher 0800 h salivary cortisol levels in G/G homozygotes (F=2.9, p=0.02). Participants homozygous for the G allele also had greater area under the curve (AUC) cortisol secretion compared to C allele carriers (F=6.4, p=0.01). Our findings suggest that being homozygous for the G allele of the MR gene polymorphism -2G/G is associated with higher cortisol levels in healthy adults, especially in the morning during peak cortisol secretion. This polymorphism may contribute to the interindividual variability in stress responsiveness and might be involved in stress-related disorders.
Collapse
Affiliation(s)
- Christoph Muhtz
- Department of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
| | | | | | | | | |
Collapse
|
24
|
Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, Zill P, Dehning S, Opgen-Rhein M, Cerovecki A, Hartmann AM, Schäfer M, Bondy B, Müller N, Möller HJ, Riedel M. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J Psychiatr Res 2011; 45:234-41. [PMID: 20598711 DOI: 10.1016/j.jpsychires.2010.06.004] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2010] [Revised: 05/17/2010] [Accepted: 06/07/2010] [Indexed: 11/30/2022]
Abstract
The HOMER 1 protein plays a crucial role in mediating glutamatergic neurotransmission. It has previously shown to be a candidate gene for etiology and pathophysiology of different psychiatric diseases such as schizophrenia. To identify genes involved in response to antipsychotics, subgroups of animals were treated with haloperidol (1 mg/kg, n = 11) or saline (n = 12) for one week. By analyzing microarray data, we replicated the observed increase of Homer 1 gene expression. Furthermore, we genotyped 267 schizophrenic patients, who were treated monotherapeutically with different antipsychotics within randomized-controlled trials. Psychopathology was measured weekly using the PANSS for a minimum of four and a maximum of twelve weeks. Correlations between PANSS subscale scores at baseline and PANSS improvement scores after four weeks of treatment and genotypes were calculated by using a linear model for all investigated SNP's. We found an association between two HOMER 1 polymorphisms (rs2290639 and rs4704560) and different PANSS subscales at baseline. Furthermore all seven investigated polymorphisms were found to be associated with therapy response in terms of a significant correlation with different PANSS improvement subscores after four weeks of antipsychotic treatment. Most significant associations have been shown between the rs2290639 HOMER 1 polymorphism and PANSS subscales both at baseline conditions and after four weeks of antipsychotic treatment. This is the first study which shows an association between HOMER 1 polymorphisms and psychopathology data at baseline and therapy response in a clinical sample of schizophrenic patients. Thus, these data might further help in detecting differential therapy response in individuals with schizophrenia.
Collapse
Affiliation(s)
- Ilja Spellmann
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University of Munich, Nußbaumstrasse 7, 80336 Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Wankerl M, Zyriax BC, Bondy B, Hinkelmann K, Windler E, Otte C. Serotonin transporter gene-linked polymorphic region (5-HTTLPR) and diurnal cortisol: A sex by genotype interaction. Biol Psychol 2010; 85:344-6. [DOI: 10.1016/j.biopsycho.2010.07.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2010] [Revised: 06/21/2010] [Accepted: 07/08/2010] [Indexed: 12/24/2022]
|
26
|
Preuss UW, Ridinger M, Rujescu D, Fehr C, Koller G, Wodarz N, Bondy B, Soyka M, Wong WM, Zill P. No association of alcohol dependence with HOMER 1 and 2 genetic variants. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:1102-9. [PMID: 20333726 DOI: 10.1002/ajmg.b.31074] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Several lines of evidence indicate that alterations of the central cortico-accumbens glutamate pathway are involved in the development and maintenance of alcohol- and substance-use disorders. The HOMER protein family is encoded by 3 genes HOMER (1-3) which are components of the excitatory postsynaptic density complex and function to modulate synaptic activity by the regulation of glutamate signaling. HOMER 1 and 2 have been reported to contribute to chronic alcohol-induced long-term neurochemical changes in the endogenous reward system. Data from animal models suggest a potential role of the Homer protein family in the development of alcohol and substance use. The aim of this study is to assess potential associations between HOMER 1 and 2 genetic variants in a larger sample of alcohol-dependent individuals and unrelated controls. Five genetic variants of HOMER 1 and 3 of HOMER 2 were genotyped in a multi-site sample of 1,923 German healthy controls and 2,039 alcohol-dependent subjects. Neither single SNP nor haplotype analysis could detect significant associations with alcohol dependence (AD) and related phenotypes. While most of the HOMER 1 and 2 SNPs are in low-to-moderate linkage disequilibrium, three major haplotypes of HOMER 1 and 4 haplotypes of HOMER 2 are present in the majority of alcohol-dependent and control subjects. In conclusion, our results suggest that single SNPs, respectively, haplotypes of the HOMER 1 and 2 genes are unlikely to play a major role in the pathophysiology of AD.
Collapse
Affiliation(s)
- U W Preuss
- Department of Psychiatry, Psychotherapy and Psychosomatics, University of Halle-Wittenberg, Halle/Saale, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Grohmann M, Hammer P, Walther M, Paulmann N, Büttner A, Eisenmenger W, Baghai TC, Schüle C, Rupprecht R, Bader M, Bondy B, Zill P, Priller J, Walther DJ. Alternative splicing and extensive RNA editing of human TPH2 transcripts. PLoS One 2010; 5:e8956. [PMID: 20126463 PMCID: PMC2813293 DOI: 10.1371/journal.pone.0008956] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2009] [Accepted: 01/08/2010] [Indexed: 11/19/2022] Open
Abstract
Brain serotonin (5-HT) neurotransmission plays a key role in the regulation of mood and has been implicated in a variety of neuropsychiatric conditions. Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the biosynthesis of 5-HT. Recently, we discovered a second TPH isoform (TPH2) in vertebrates, including man, which is predominantly expressed in brain, while the previously known TPH isoform (TPH1) is primarly a non-neuronal enzyme. Overwhelming evidence now points to TPH2 as a candidate gene for 5-HT-related psychiatric disorders. To assess the role of TPH2 gene variability in the etiology of psychiatric diseases we performed cDNA sequence analysis of TPH2 transcripts from human post mortem amygdala samples obtained from individuals with psychiatric disorders (drug abuse, schizophrenia, suicide) and controls. Here we show that TPH2 exists in two alternatively spliced variants in the coding region, denoted TPH2a and TPH2b. Moreover, we found evidence that the pre-mRNAs of both splice variants are dynamically RNA-edited in a mutually exclusive manner. Kinetic studies with cell lines expressing recombinant TPH2 variants revealed a higher activity of the novel TPH2B protein compared with the previously known TPH2A, whereas RNA editing was shown to inhibit the enzymatic activity of both TPH2 splice variants. Therefore, our results strongly suggest a complex fine-tuning of central nervous system 5-HT biosynthesis by TPH2 alternative splicing and RNA editing. Finally, we present molecular and large-scale linkage data evidencing that deregulated alternative splicing and RNA editing is involved in the etiology of psychiatric diseases, such as suicidal behaviour.
Collapse
Affiliation(s)
- Maik Grohmann
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
- Department of Biology, Chemistry, and Pharmacy, Free University Berlin, Berlin, Germany
- Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin, Berlin, Germany
| | - Paul Hammer
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - Maria Walther
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - Nils Paulmann
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
- Department of Biology, Chemistry, and Pharmacy, Free University Berlin, Berlin, Germany
| | - Andreas Büttner
- Institute for Legal Medicine, Ludwig Maximilians University, Munich, Germany
| | | | - Thomas C. Baghai
- Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
| | - Cornelius Schüle
- Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
| | - Rainer Rupprecht
- Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
| | - Michael Bader
- Laboratory of Molecular Biology of Peptide Hormones, Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Brigitta Bondy
- Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
| | - Peter Zill
- Department of Psychiatry, Ludwig Maximilians University, Munich, Germany
| | - Josef Priller
- Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin, Berlin, Germany
| | - Diego J. Walther
- Department of Human Molecular Genetics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| |
Collapse
|
28
|
Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, Zill P, Dehning S, Hartmann A, Bondy B, Müller N, Möller HJ, Riedel M. S28-03 - Pharmacogenetics of therapy response in schizophrenia. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)70063-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
29
|
Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Müller-Myhsok B. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. ACTA ACUST UNITED AC 2009; 66:966-975. [PMID: 19736353 DOI: 10.1001/archgenpsychiatry.2009.95] [Citation(s) in RCA: 258] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
CONTEXT The efficacy of antidepressant drug treatment in depression is unsatisfactory; 1 in 3 patients does not fully recover even after several treatment trials. Genetic factors and clinical characteristics contribute to the failure of a favorable treatment outcome. OBJECTIVE To identify genetic and clinical determinants of antidepressant drug treatment outcome in depression. DESIGN Genomewide pharmacogenetic association study with 2 independent replication samples. SETTING We performed a genomewide association study in patients from the Munich Antidepressant Response Signature (MARS) project and in pooled DNA from an independent German replication sample. A set of 328 single-nucleotide polymorphisms highly related to outcome in both genomewide association studies was genotyped in a sample of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. PARTICIPANTS A total of 339 inpatients with a depressive episode (MARS sample), a further 361 inpatients with depression (German replication sample), and 832 outpatients with major depression (STAR*D sample). MAIN OUTCOME MEASURES We generated a multilocus genetic variable that described the individual number of alleles of the selected single nucleotide polymorphisms associated with beneficial treatment outcome in the MARS sample ("response" alleles) to evaluate additive genetic effects on antidepressant drug treatment outcome. RESULTS Multilocus analysis revealed a significant contribution of a binary variable that categorized patients as carriers of a high vs low number of response alleles in the prediction of antidepressant drug treatment outcome in both samples (MARS and STAR*D). In addition, we observed that patients with a comorbid anxiety disorder combined with a low number of response alleles showed the least favorable outcome. CONCLUSION These results demonstrate the importance of multiple genetic factors combined with clinical features in the prediction of antidepressant drug treatment outcome, which underscores the multifactorial nature of this trait.
Collapse
Affiliation(s)
- Marcus Ising
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Susanne Lucae
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Elisabeth B Binder
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Thomas Bettecken
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Manfred Uhr
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Stephan Ripke
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Martin A Kohli
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Johannes M Hennings
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Sonja Horstmann
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Stefan Kloiber
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Andreas Menke
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Brigitta Bondy
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Rainer Rupprecht
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Katharina Domschke
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Bernhard T Baune
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Volker Arolt
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - A John Rush
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Florian Holsboer
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| | - Bertram Müller-Myhsok
- Max Planck Institute of Psychiatry, Munich, Germany (Drs Ising, Lucae, Binder, Bettecken, Uhr, Ripke, Kohli, Hennings, Horstmann, Kloiber, Menke, Holsboer, and Müller-Myhsok), Department of Psychiatry, Ludwig Maximilians University, Munich, Germany (Drs Bondy and Rupprecht), Department of Psychiatry, Westfalian Wilhelms University Muenster, Muenster, Germany (Drs Domschke, Baune, and Arolt), Department of Psychiatry, James Cook University, Townsville, Australia (Dr Baune), Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA, and Department of Clinical Sciences, Duke-NUS, Singapore (Dr Rush)
| |
Collapse
|
30
|
Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Müller-Myhsok B. A genome-wide association study points to multiple loci predicting antidepressant treatment outcome in depression. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Palm U, Fintescu Z, Schiller C, Reisinger E, Keeser D, Bondy B, Padberg F. BDNF plasma level changes after transcranial direct current stimulation in major depressive disorder. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Koller G, Zill P, Fehr C, Pogarell O, Bondy B, Soyka M, Preuss UW. No association of alcohol dependence with SLC6A5 and SLC6A9 glycine transporter polymorphisms. Addict Biol 2009; 14:506-8. [PMID: 19650813 DOI: 10.1111/j.1369-1600.2009.00170.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To determine whether glycine transporter polymorphisms are associated with alcoholism, three genetic variants of SLC6A5 and two polymorphisms of SLC6A9 were genotyped in 463 German non-alcoholic controls and 644 German alcohol-dependent subjects. Association was investigated employing chi-square statistics and haplotype analysis. There was a significant association between the SLC6A5 polymorphism (rs1443547) and alcohol dependence as alcoholic individuals had a lower rate of AG-allele (chi(2) = 6.048, P = 0.049, d.f. = 2), which did not remain significant after correction for multiple testing. There was no association between SLC6A9 glycine transporter polymorphisms and alcohol dependence, and also none in haplotype analysis.
Collapse
Affiliation(s)
- Gabriele Koller
- Psychiatrische Klinik, Nussbaumstrasse 7, 80336 Munich, Germany.
| | | | | | | | | | | | | |
Collapse
|
33
|
Koller G, Zill P, Pogarell O, Bondy B, Soyka M. No association of alcohol dependence with SLC6A5 and SLC6A9 glycine transporter polymorphisms. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
34
|
Schennach-Wolff R, Zill P, Jäger M, Seemüller F, Obermeier M, Bondy B, Möller HJ, Riedel M. Outcome of suicidal patients with schizophrenia and the possible genetic association: results from a naturalistic study. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Zill P, Vielsmeier V, Büttner A, Eisenmenger W, Bondy B, Möller HJ. Comparative proteomic analysis with human post mortem brain tissues of drug addicts versus controls: possible impact of beta-tubulin on drug abusing behaviour. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Hartmann AM, Giegling I, Genius J, Schäfer M, Bondy B, Möller HJ, Rujescu D. Pharmacogenetics of antipsychotics using an animal model. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Spellmann I, Rujescu D, Musil R, Giegling I, Mayr A, Zill P, Dehning S, Cerovecki A, Bondy B, Müller N, Möller HJ, Riedel M. Pharmacogenetics of therapy response in schizophrenia. Pharmacopsychiatry 2009. [DOI: 10.1055/s-0029-1240227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
38
|
Haefner S, Baghai TC, Schule C, Eser D, Spraul M, Zill P, Rupprecht R, Bondy B. Impact of gene-gender effects of adrenergic polymorphisms on hypothalamic-pituitary-adrenal axis activity in depressed patients. Neuropsychobiology 2009; 58:154-62. [PMID: 19088492 DOI: 10.1159/000182891] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2008] [Accepted: 10/05/2008] [Indexed: 11/19/2022]
Abstract
OBJECTIVE There is overwhelming evidence that activation of the hypothalamic-pituitary-adrenal (HPA) system plays a major role in depression and cardiovascular disease in genetically susceptible individuals. We hypothesized that due to the multiple interactions between the sympathetic and the HPA systems via adrenoceptors, polymorphisms in these genes could have an impact on HPA axis activity in major depression. METHODS Using the dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test, we investigated the association of alpha(2)-adrenoceptor (ADRA2A -1291C-->G) and the beta(2)-adrenoceptor gene (ADRB2 Arg16Gly) in 189 patients with major depression during the acute state of the disease and after remission. RESULTS Male ADRA2A -1291G allele homozygotes showed significant pretreatment HPA axis hyperactivity, with increased adrenocorticotropin (ACTH; F = 4.9, d.f. = 2, p = 0.009) and cortisol responses (F = 6.4, d.f. = 2, p = 0.003). In contrast, female ADRB2 Arg/Arg homozygotes had increased pretreatment ACTH (F = 7.17, d.f. = 2, p = 0.001) and cortisol (F = 8.95, d.f. = 2, p = 0.000) levels. Interestingly, in the respective genotypes, the stress hormones remained elevated in the second DEX/CRH test, despite a reduction in depressive symptoms. CONCLUSIONS This study provides evidence that, depending on gender and polymorphisms, there is continuous HPA axis overdrive in a proportion of patients irrespective of the status of depression. Considering the importance of stress hormones for cardiovascular disorders, our data might suggest that these patients are at high risk of comorbidity between depression and cardiovascular disorders.
Collapse
Affiliation(s)
- S Haefner
- Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Munich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Schüle C, Baghai TC, Eser D, Schwarz M, Bondy B, Rupprecht R. Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients. J Psychiatr Res 2009; 43:538-45. [PMID: 18706658 DOI: 10.1016/j.jpsychires.2008.07.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2008] [Revised: 06/24/2008] [Accepted: 07/07/2008] [Indexed: 10/21/2022]
Abstract
BACKGROUND Among the neuroactive steroids, dehydroepiandrosterone sulfate (DHEA-S) is at least in part produced in the adrenal gland and is therefore under the control of the hypothalamic-pituitary-adrenocortical (HPA)-system. In the present study, the impact of mirtazapine on DHEA-S and cortisol (COR) levels was investigated in relation to clinical response in depressed patients. METHODS A total of 23 inpatients suffering from a major depressive episode (DSM-IV criteria) underwent 5-week treatment with mirtazapine (45 mg/day). Plasma samples were taken weekly at 0800 h and quantified for COR and DHEA-S levels. RESULTS Mirtazapine significantly reduced both COR and DHEA-S concentrations, but had no impact on the COR/DHEA-S ratio. The percentage decrease of DHEA-S, but not that of COR was significantly and positively correlated with the percentage reduction in the sum score of the Hamilton Depression Rating Scale at week 5, suggesting a relationship between DHEA-S reduction and clinical efficacy of mirtazapine. There was a significant positive correlation between the decline in COR and DHEA-S levels. CONCLUSIONS Apparently, the decrease in COR and DHEA-S concentrations conjointly reflects an attenuating impact of mirtazapine on HPA axis activity, thereby decreasing the adrenal secretion of COR and DHEA-S.
Collapse
Affiliation(s)
- Cornelius Schüle
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Nussbaumstrasse 7, 80336 Munich, Germany.
| | | | | | | | | | | |
Collapse
|
40
|
Zill P, Büttner A, Eisenmenger W, Müller J, Möller HJ, Bondy B. Predominant expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem study in human brain. Neuroscience 2009; 159:1274-82. [PMID: 19233335 DOI: 10.1016/j.neuroscience.2009.01.006] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2008] [Revised: 12/18/2008] [Accepted: 01/04/2009] [Indexed: 10/21/2022]
Abstract
Although the predominant role of tryptophan hydroxylase 2 (TPH2) in the CNS and its influence on the vulnerability to psychiatric disorders have clearly been demonstrated in several studies, the role of TPH1 on neuronal mechanisms, respectively on behavioral traits is still poorly understood. In a previous study of tryptophan hydroxylase 1 (TPH1) and TPH2 mRNA expression in different human brain regions we observed significantly higher TPH1 than TPH2 mRNA concentrations in the pituitary (unpublished observations). Considering the importance of the pituitary in the functional circuits between brain and body, we investigated the TPH1 and TPH2 mRNA expression in more detail, using human postmortem samples of the posterior and anterior pituitary compared to cortex, hippocampus and raphe nuclei. Specimens were available from different psychiatric patients (drug abusers, n=12; suicide victims, n=11; schizophrenics, n=9) and controls (n=15). Additionally we performed immunohistochemical analysis applying monospecific antibodies for both TPH isoforms to verify that the mRNA is of cellular and not just vascular or other origin. Highest TPH2 mRNA levels were observed in the raphe nuclei in patients and controls. By contrast, in the anterior and posterior pituitary TPH1 was found to be the predominantly expressed isoform in all subgroups. TPH1 and TPH2 mRNA expression in the further brain regions was only marginal and nearly identical except in the hypothalamus where higher TPH1 than TPH2 mRNA levels could be measured. Interindividual differences between the subgroups were not detectable. The results of the present study extended our previous findings by the additional immunohistochemical determination of the neuronal TPH1 and TPH2 protein expression in the anterior pituitary and provide evidence against a strictly separated duality of the serotonergic system. It seems that TPH1 might also have an impact on neuronal mechanisms via hypothalamic-pituitary-adrenal axis regulation by its predominant localization in the pituitary. These observations may open up new research strategies not only for several psychiatric disorders, but also for the relationship between psychiatric and somatic diseases.
Collapse
Affiliation(s)
- P Zill
- Department of Psychiatry, Ludwig-Maximilians-University Munich, Munich, Germany.
| | | | | | | | | | | |
Collapse
|
41
|
Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schule C, Eser D, von Schacky C, Rupprecht R, Bondy B. A polymorphism in the angiotensin-converting enzyme gene is associated with smoking behavior. J Clin Psychiatry 2008; 69:1983-5. [PMID: 19203483 DOI: 10.4088/jcp.v69n1219c] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
42
|
Frodl T, Zill P, Baghai T, Schüle C, Rupprecht R, Zetzsche T, Bondy B, Reiser M, Möller HJ, Meisenzahl EM. Reduced hippocampal volumes associated with the long variant of the tri- and diallelic serotonin transporter polymorphism in major depression. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1003-7. [PMID: 18286634 DOI: 10.1002/ajmg.b.30680] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Substantial evidence supports a role for dysfunction of the serotonin transporter (5-HTT) in the pathogenesis of major depression. The polymorphism of the serotonin transporter gene (5-HTTLPR) was found to be associated with reduced hippocampal volume in major depression. However, the original diallelic polymorphism was criticized, because the L-allele can be subtyped into La and Lg alleles, the latter of which is thought to be similar to the S-allele. Therefore, the study aim was to examine the influences of the triallelic (La-Lg-S system) and diallelic 5-HTTLPR on hippocampal volumes in patients with major depression and healthy controls. Using high-resolution MRI hippocampal volumes and polymorphisms (5-HTTLPR) were measured in 60 in-patients with major depression and 60 healthy controls. Patients with the La/La genotype had significantly smaller hippocampal gray and white matter than La/La controls. No significant differences were found between patients and controls with La/(Lg + S) or (Lg + S)/(Lg + S) genotype. Moreover, within the patient group the La/La homozygous genotype had significantly smaller hippocampal white matter volumes than the La/(Lg + S) or (Lg + S)/(Lg + S) genotype. In conclusion, with the diallelic as well as the triallelic system the homozygosity for the long-allele is associated with decreased hippocampal volumes in patients with major depression, but not in healthy controls, suggesting that disease or stress specific processes linked to the serotonergic system may enhance the vulnerability to morphological alterations.
Collapse
Affiliation(s)
- Thomas Frodl
- Department of Psychiatry, Ludwig-Maximilians-University of Munich, Munich, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Musil R, Spellmann I, Riedel M, Dehning S, Douhet A, Maino K, Zill P, Müller N, Möller HJ, Bondy B. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res 2008; 42:963-70. [PMID: 18191416 DOI: 10.1016/j.jpsychires.2007.11.003] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2007] [Revised: 10/16/2007] [Accepted: 11/06/2007] [Indexed: 10/22/2022]
Abstract
Drug induced weight gain is a serious side effect of several atypical antipsychotics. As genetic factors play an important role in the homeostasis of hunger/satiety we tried to replicate a preliminary previous finding about an impact of three polymorphisms in the synaptosomal-associated protein of 25kDa (SNAP-25; sites MnlI, TaiI and DdelI in the 3(')-UTR) on clinical response and antipsychotic induced weight gain. We genotyped 162 schizophrenic patients being treated in monotherapy with atypical antipsychotics and 312 healthy control subjects for the three polymorphisms in the SNAP-25 gene using PCR. PANSS scores and weight were measured weekly for a minimum of five weeks. We found significant associations between the TaiI and MnlI polymorphisms and serum triglyceride levels at baseline and for the DdelI polymorphism and weight gain. In conclusion our study can at least partly replicate the previous findings concerning the impact of SNAP-25 gene polymorphisms on weight gain during antipsychotic treatment.
Collapse
Affiliation(s)
- Richard Musil
- Psychiatric Clinic of University Munich, Nussbaumstrasse 7, 80336 Munich, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Zetzsche T, Preuss UW, Bondy B, Frodl T, Zill P, Schmitt G, Koutsouleris N, Rujescu D, Born C, Reiser M, Möller HJ, Meisenzahl EM. 5-HT1A receptor gene C -1019 G polymorphism and amygdala volume in borderline personality disorder. Genes Brain Behav 2008; 7:306-13. [PMID: 18387137 DOI: 10.1111/j.1601-183x.2007.00353.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Alterations of amygdala structure and function have been repeatedly described in patients with borderline personality disorder (BPD). The aim of our study was to determine whether a functional polymorphism of the 5-hydroxytryptamine(1A) receptor (5-HTR(1A)) gene C -1019 G (identity number: rs6295 G/C) is associated with structural changes of the amygdala in patients with BPD. Twenty-five right-handed female inpatients with BPD according to DSM IV and 25 healthy controls matched for age, sex, handedness and educational status were enrolled. Brain volumetry of the amygdala was performed with a 1.5-T Magnetom Vision apparatus (Siemens, Erlangen, Germany) and analyzed by the software program 'BRAINS'. Patients who have the 5-HTR(1A) gene G allele had significantly smaller amygdala volumes than C/C genotype carriers (P = 0.02). While no difference of allelic distribution between patients and controls was detected, the described effect of 5-HTR(1A) genotype on amygdala volume was found for the whole group of patients, as well as in the subgroup of patients with comorbid major depression (P = 0.004) but not in controls. In contrast to these subgroups of BPD patients who had significant amygdala volume differences, the mean amygdala volume of the whole group of BPD patients was not significantly different from that of controls. In summary, our study provides first evidence that 5-HTR(1A) gene C -1019 G polymorphism is associated with structural changes in the limbic system of BPD patients, a finding that might be disease related and might contribute to explanation of previous discrepant results regarding amygdala volume changes in BPD. Future research is recommended to clarify possible interactions between this functional polymorphism and symptoms, course and treatment responses in this disorder.
Collapse
Affiliation(s)
- T Zetzsche
- Department of Psychiatry and Psychotherapy, Ludwig-Maximilians University, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Willeit M, Sitte HH, Thierry N, Michalek K, Praschak-Rieder N, Zill P, Winkler D, Brannath W, Fischer MB, Bondy B, Kasper S, Singer EA. Enhanced serotonin transporter function during depression in seasonal affective disorder. Neuropsychopharmacology 2008; 33:1503-13. [PMID: 17882235 DOI: 10.1038/sj.npp.1301560] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Decreased synaptic serotonin during depressive episodes is a central element of the monoamine hypothesis of depression. The serotonin transporter (5-HTT, SERT) is a key molecule for the control of synaptic serotonin levels. Here we aimed to detect state-related alterations in the efficiency of 5-HTT-mediated inward and outward transport in platelets of drug-free depressed patients suffering from seasonal affective disorder (SAD). 5-HTT turnover rate, a measure for the number of inward transport events per minute, and tyramine-induced, 5-HTT-mediated outward transport were assessed at baseline, after 4 weeks of bright light therapy, and in summer using a case-control design in a consecutive sample of 73 drug-free depressed patients with SAD and 70 nonseasonal healthy controls. Patients were drug-naive or medication-free for at least 6 months prior to study inclusion, females patients were studied in the follicular phase of the menstrual cycle. All participants were genotyped for a 5-HTT-promoter polymorphism (5-HTTLPR) to assess the influence of this polymorphism on 5-HTT parameters. Efficiency of 5-HTT-mediated inward (p=0.014) and outward (p=0.003) transport was enhanced in depressed patients. Both measures normalized toward control levels after therapy and in natural summer remission. Changes in outward transport showed a clear correlation with treatment response (rho=0.421, p=0.001). Changes in inward transport were mediated by changes in 5-HTT transport efficiency rather than affinity or density. 5-HTTLPR was not associated with any of the 5-HTT parameters. In sum, we conclude that the 5-HTT is in a hyperfunctional state during depression in SAD and normalizes after light therapy and in natural summer remission.
Collapse
Affiliation(s)
- Matthäus Willeit
- Department of Biological Psychiatry, Medical University of Vienna, Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bondy B, Ackenheil M, Bak R, Feistenauser E, Fröhler M. Catecholamine - Receptors on Blood Cells of Untreated Schizophrenic Patients. Pharmacopsychiatry 2008. [DOI: 10.1055/s-2007-1017350] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Fröhler M, Saito Y, Ackenheil M, Bak R, Bondy B, Feistenauer E, Hofschuster E, Vakis A, Welter D. Catecholaminergic Binding Sites on Blood Cells of Healthy Volunteers with Special Respect to Circadian Rhythms. Pharmacopsychiatry 2008. [DOI: 10.1055/s-2007-1017349] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Zill P, Preuss UW, Koller G, Bondy B, Soyka M. Analysis of Single Nucleotide Polymorphisms and Haplotypes in the Neuropeptide Y Gene: No Evidence for Association With Alcoholism in a German Population Sample. Alcohol Clin Exp Res 2008; 32:430-4. [DOI: 10.1111/j.1530-0277.2007.00586.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
49
|
Geretsegger C, Bitterlich W, Stelzig R, Stuppaeck C, Bondy B, Aichhorn W. Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. Eur Neuropsychopharmacol 2008; 18:141-6. [PMID: 18054209 DOI: 10.1016/j.euroneuro.2007.09.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2007] [Revised: 08/31/2007] [Accepted: 09/21/2007] [Indexed: 10/22/2022]
Abstract
Pindolol, a 5-HT1A autoreceptor antagonist, given in combination with selective serotonin reuptake inhibitors (SSRIs), may enhance and/or accelerate the therapeutic efficacy of SSRIs. Fifty patients, meeting ICD-10 criteria for major depressive disorder or bipolar depression, were enrolled in our randomized, placebo-controlled, double-blind trial. One group received paroxetine plus pindolol (2.5 mg t.i.d.), and the other group received paroxetine plus placebo. The proportion of patients with sustained response (>or=50% reduction of baseline HAM-D 17 score maintained until the endpoint; p=0.252) and the proportion of patients with remission (HAM-D 17 <or=8 at last visit; p=0.769) did not differ significantly between the two treatment groups. However, a significantly greater proportion of patients who were not previously treated with antidepressants (n=15; p=0.041) and of patients with bipolar depression (n=11; p=0.015) had a sustained response in the paroxetine plus pindolol group compared to the paroxetine plus placebo group; furthermore there was a trend for first episode depressed patients to have a greater response in the paroxetine plus pindolol group (n=12; p=0.071). Summarizing, the entire study population showed no antidepressive benefit from pindolol augmentation. Nevertheless patients with bipolar depression irrespective of previous treatments and duration of illness, and unipolar patients not previously treated demonstrated a significant benefit from pindolol augmentation.
Collapse
Affiliation(s)
- Christian Geretsegger
- University Clinics of Psychiatry and Psychotherapy I, Paracelsus Medical University, Ignaz-Harrer-Str. 79, 5020 Salzburg, Austria.
| | | | | | | | | | | |
Collapse
|
50
|
Abstract
Gamma-aminobutyric acid (GABA) A receptors are believed to mediate some of the physiological and behavioral actions of ethanol. Recent studies have suggested that genetic variants of the GABA-A receptor alpha2 subunit gene (GABRA2) are associated with alcohol dependence. The aim of this study is to confirm and extend the role of GABRA2 haplotypes in the liability to alcohol dependence. 291 (231 male) treatment-seeking alcohol-dependent individuals and 295 (153 male) control subjects were enrolled into the study. Characteristics of alcohol dependence were obtained using the SSAGA (semi-structured assessment of the genetics of alcoholism, German Version). Genotyping of 10 SNPs across the GABRA2 gene was performed following previous reports and using PCR. One genetic variant was detected to significantly differ between alcohol-dependent subjects and controls. Two common 8 SNP haplotypes and their complementary alleles were identified containing this SNP and were present in 89.9% of controls and 93.4% of the alcohol-dependent individuals. One of the haplotypes (T-C-A-C-A-T-T-C) was significantly associated with alcohol dependence and characteristics of alcohol withdrawal and severity of alcohol dependence (delirium tremens, withdrawal seizures). These findings support and extend the three previous studies implicating a GABA-A receptor subunit as contributing to the genetic risk for alcohol dependence. Possible implications of these findings are discussed.
Collapse
Affiliation(s)
- M Soyka
- Psychiatric Hospital of Ludwig-Maximilians-University Munich, Germany.
| | | | | | | | | | | |
Collapse
|